Provided by Tiger Fintech (Singapore) Pte. Ltd.

Tonix Pharmaceuticals

13.37
-0.2600-1.91%
Volume:281.42K
Turnover:3.81M
Market Cap:74.74M
PE:-1.72
High:14.06
Open:13.84
Low:13.13
Close:13.63
Loading ...

Tonix Pharmaceuticals Secures US Patent for Migraine Treatment -- Shares Rise Pre-Bell

MT Newswires Live
·
19 Sep 2024

BRIEF-Tonix Pharmaceuticals Announces Issuance Of U.S. Patent For FDA-Approved Tosymra® To Treat Migraines

Reuters
·
19 Sep 2024

Tonix Pharmaceuticals Announces Issuance of U.S. Patent by the United States Patent and Trademark Office Covering the Intranasal Delivery of FDA-Approved Tosymra® to Treat Migraines

THOMSON REUTERS
·
19 Sep 2024

Tonix Pharmaceuticals Holding Corp: New Patent Expected to Expire in 2030

THOMSON REUTERS
·
19 Sep 2024

Tonix Pharmaceuticals Announces Issuance of U.S. Patent by the United States Patent and Trademark Office Covering the Intranasal Delivery of FDA-Approved Tosymra® to Treat Migraines

GlobeNewswire
·
19 Sep 2024

New Hope for Mpox? How TNX-801 Could Meet the WHO's Vaccine Targets for a Safer, Single-Dose Solution

ACCESSWIRE
·
18 Sep 2024

BRIEF-Tonix Pharmaceuticals Announces That Its Single Dose Mpox Vaccine Candidate Tnx-801 Aligns With Who's Newly Issued Preferred Target Product Profile For Mpox Vaccines In Global Health Emergency

Reuters
·
16 Sep 2024

Tonix Pharmaceuticals Announces That Its Single Dose Mpox Vaccine Candidate Tnx-801 Aligns With Who’s Newly Issued Preferred Target Product Profile for Mpox Vaccines in Global Health Emergency

THOMSON REUTERS
·
16 Sep 2024

Tonix Pharmaceuticals Announces That its Single Dose Mpox Vaccine Candidate TNX-801 Aligns with WHO’s Newly Issued Preferred Target Product Profile for Mpox Vaccines in Global Health Emergency

GlobeNewswire
·
16 Sep 2024